盛弘 8403
OTC · Biotechnology and medical care- Open
- —
- High
- —
- Low
- —
- Prev close
- —
- Volume (lots)
- —
- Turnover
- —
- P/E
- 12.4
- Cash yield
- 3.29%
Financial trends
Loading…
Consolidated statements; NT$100M (per-share items in NT$). Updated after each quarterly filing (MOPS). Some line items do not apply to financial companies.
Unit: 100 million TWD (EPS in TWD)Source: public data from MOPS, TWSE, TPEx and TDCC
Loading…
Figures are shown as announced, with no scoring or rating.
No data.
No data.
Revenue in NT$100M; 12 months per page.
| Item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 12.3 | 11.9 | 10.8 | 11.3 | 11.1 | 10.7 | 10.5 | 11.1 |
| Cost of revenue | 10.1 | 9.8 | 9.3 | 9.5 | 9.2 | 9.0 | 8.8 | 9.4 |
| Gross profit | 2.2 | 2.1 | 1.5 | 1.7 | 1.8 | 1.8 | 1.7 | 1.7 |
| Operating expenses | 1.5 | 1.5 | 1.5 | 1.3 | 1.6 | 1.7 | 1.6 | 2.1 |
| Other operating items | 0.1 | 0.2 | 0.2 | 0.3 | 0.2 | 0.2 | 0.2 | 1.4 |
| Operating income | 0.8 | 0.7 | 0.2 | 0.7 | 0.5 | 0.2 | 0.3 | 1.0 |
| Non-operating items | 0.0 | 0.1 | -0.0 | -0.0 | -0.1 | -0.1 | -0.0 | -0.3 |
| Pre-tax income | 0.9 | 0.8 | 0.2 | 0.7 | 0.4 | 0.2 | 0.3 | 0.7 |
| Income tax | 0.2 | 0.1 | 0.1 | 0.1 | 0.1 | 0.0 | 0.1 | 0.1 |
| Continuing operations | 0.7 | 0.6 | 0.1 | 0.6 | 0.2 | 0.1 | 0.2 | 0.6 |
| Net income | 0.7 | 0.6 | 0.1 | 0.6 | 0.2 | 0.1 | 0.2 | 0.6 |
| Net income to parent | 0.7 | 0.6 | 0.2 | 0.5 | 0.3 | 0.3 | 0.3 | 0.9 |
| Net income to NCI | -0.0 | 0.0 | -0.1 | 0.1 | -0.1 | -0.1 | -0.1 | -0.3 |
| Other comprehensive income | -0.0 | -0.8 | -0.4 | -2.2 | 0.7 | -0.1 | -0.4 | -0.4 |
| Total comprehensive income | 0.7 | -0.2 | -0.3 | -1.6 | 0.9 | 0.0 | -0.2 | 0.2 |
| EPS (TWD) | 0.52 | 0.45 | 0.13 | 0.38 | 0.20 | 0.21 | 0.24 | 0.67 |
Amounts in NT$100M (per-share items in NT$).
| Item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|
| Current assets | 30.2 | 31.1 | 30.8 | 31.3 | 31.6 | 31.4 | 32.1 | 33.9 |
| Non-current assets | 34.1 | 34.3 | 34.5 | 34.8 | 36.0 | 35.9 | 36.3 | 37.1 |
| Total assets | 64.2 | 65.4 | 65.3 | 66.2 | 67.6 | 67.3 | 68.4 | 71.0 |
| Current liabilities | 14.9 | 16.2 | 15.3 | 15.6 | 15.7 | 16.2 | 16.0 | 18.6 |
| Non-current liabilities | 11.9 | 12.2 | 12.0 | 12.2 | 11.8 | 12.1 | 12.8 | 12.6 |
| Total liabilities | 26.7 | 28.4 | 27.3 | 27.8 | 27.5 | 28.3 | 28.8 | 31.2 |
| Share capital | 13.8 | 13.8 | 13.8 | 13.8 | 13.8 | 13.8 | 13.1 | 13.1 |
| Capital surplus | 11.3 | 11.3 | 11.5 | 11.5 | 11.5 | 11.5 | 11.5 | 11.5 |
| Retained earnings | 9.2 | 8.4 | 10.8 | 10.6 | 10.1 | 9.8 | 10.8 | 10.5 |
| Other equity | -0.6 | -0.5 | -1.8 | -1.4 | 0.7 | 0.0 | 0.1 | 0.5 |
| Equity to parent | 33.6 | 33.0 | 34.2 | 34.4 | 36.1 | 35.1 | 35.5 | 35.6 |
| Non-controlling interests | 3.9 | 4.0 | 3.8 | 3.9 | 4.1 | 3.9 | 4.1 | 4.2 |
| Total equity | 37.5 | 37.0 | 38.0 | 38.3 | 40.2 | 39.0 | 39.6 | 39.8 |
| Book value per share (TWD) | 24.44 | 23.97 | 24.86 | 25.02 | 26.23 | 26.76 | 27.09 | 27.13 |
Amounts in NT$100M (per-share items in NT$).
| Item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 0.7 | 1.5 | 0.3 | 1.1 | 1.1 | 1.8 | -0.4 | 0.6 |
| Investing cash flow | -0.7 | 0.6 | -0.3 | -2.0 | -0.0 | -1.0 | 1.8 | 0.4 |
| Financing cash flow | -1.5 | -0.9 | -0.3 | -0.6 | -1.0 | -1.3 | -0.7 | -0.7 |
| FX effect | 0.0 | 0.0 | 0.0 | 0.0 | -0.0 | -0.0 | 0.0 | 0.0 |
| Net change in cash | -1.5 | 1.2 | -0.2 | -1.4 | 0.0 | -0.5 | 0.7 | 0.3 |
| Cash, beginning | 13.4 | 13.4 | 13.4 | 14.6 | 14.6 | 14.6 | 14.6 | 13.8 |
| Cash, ending | 12.9 | 14.4 | 13.1 | 13.4 | 14.8 | 14.8 | 15.3 | 14.6 |
Amounts in NT$100M (per-share items in NT$).
No data.
No data.
Source: MOPS. For reference only; not investment advice.